The customer is a global company developing innovative drugs and vaccines using advanced mRNA technology. The collaboration, currently in the development phase, involves the use of Bio-Works’ products and expertise in the purification of biological drugs.

The customer’s decision to move forward with Bio-Works means the company’s solutions will be used in the continued development of the drug candidate, with potential for the project to expand further if development proceeds as planned.

“We are delighted by the trust shown by yet another leading American biotech company. This order, valued at SEK 2.8 million, is an important confirmation of Bio-Works’ technical expertise and our ability to meet the demanding requirements of developing and manufacturing advanced biological drugs,” says Lone Carlbom, CEO of Bio-Works.

The collaboration strengthens Bio-Works’ position in the US market and in the fast-growing field of next-generation therapeutics. The customer’s identity and further project details cannot be disclosed due to commercial confidentiality.